Straits Times Index
3,291.48 -5.41 (-0.16%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,200.64 +28.49 (+0.35%) Bitcoin USD
59,331.83 +1,543.29 (+2.67%) CMC Crypto 200
1,282.28 +5.30 (+0.42%)
Corvus Pharmaceuticals, Inc. (CRVS)
After hours:
| Previous close | 1.6100 |
| Open | 1.7600 |
| Bid | 1.6700 x 100 |
| Ask | 1.7900 x 100 |
| Day's range | 1.6800 - 1.7800 |
| 52-week range | 1.0500 - 4.1900 |
| Volume | |
| Avg. volume | 203,237 |
| Market cap | 84.837M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5600 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.63 |
GlobeNewswireCorvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on May 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307
- GlobeNewswire
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to raise approximately $30.6 million dollars in aggregate gross proceeds through the sale of shares of its common stock, par value $0.0001 per share (the “Common Stock”) and pre-funded warrants to purchase Commo
ZacksHere's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
